Journal
AMERICAN JOURNAL OF CLINICAL NUTRITION
Volume 93, Issue 4, Pages 901S-905SPublisher
AMER SOC NUTRITION-ASN
DOI: 10.3945/ajcn.110.001941
Keywords
-
Categories
Funding
- NIDDK NIH HHS [5R37DK28082-28] Funding Source: Medline
Ask authors/readers for more resources
Fibroblast growth factor 21 (FGF21) was originally identified as a member of the FGF family in homology studies and is a member of the endocrine FGF subfamily that lacks heparin binding domains and is released into the circulation. A potential role as a metabolic regulator emerged when FGF21 was shown to increase glucose uptake in adipocytes. Subsequently, marked elevations in FGF21 expression were observed in mice that ate a ketogenic diet and when fasting, which suggests that FGF21 expression plays a role in the adaptation to metabolic states that require increased fatty acid oxidation. Consistent with this evidence, FGF21 knockout mice were not able to respond appropriately to consumption of a ketogenic diet. FGF21 expression is downstream of peroxisome proliferator-activated receptor (PPAR) alpha in the liver and PPAR gamma in adipose tissue. FGF21 concentrations are higher in both rodent and human obesity, and recent data suggest that obesity may be an FGF21-resistant state. Recent data increasingly suggest that FGF21 is an important metabolic regulator that may have potential clinical implications. Am J Clin Nutr 2011;93(suppl):901S-5S.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available